Jazz Pharmaceuticals plc [JAZZ] - Jazz Pharmaceuticals / Actio Biosciences merger
Jazz Pharmaceuticals plc will acquire Actio Biosciences, Inc. for an Aggregate Upfront Transaction Value of $820 million, with each share of Actio to be converted into a pro-rata share of this value at the effective time of the merger.
Why this matters
Jazz Pharmaceuticals plc, a company engaged in the development and commercialization of pharmaceutical products, has announced its acquisition of Actio Biosciences, Inc. for an aggregate upfront transaction value of $820 million. This strategic move involves converting each share of Actio into a pro-rata share of the transaction value at the effective time of the merger. The merger agreement, dated August 10, 2026, includes Jazz Pharmaceuticals, Actio Biosciences, Knight Acquisition Corp., and Shareholder Representative Services LLC as parties involved in the transaction.